ClinicalTrials.gg

TargetBeta

PTK7

protein tyrosine kinase 7 (inactive) · also CCK4 · I-set domain containing

5 programs in company-led studies act on PTK7, from 5 companies: 0 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
Anti-PTK7 Antibody-drug Conjugate SKB518ruleSichuan Kelun Pharmaceuticalphase 233 running–NCIt
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleIDEAYA Biosciencesphase 111 runningCD276NCIt
Anti-PTK7 Antibody-drug Conjugate HWK-007ruleWhitehawk Therapeuticsphase 111 running–NCIt
Anti-PTK7/Exatecan Antibody-drug Conjugate DAY301ruleDay One Biopharmaceuticalsphase 111 running–NCIt
Anti-PTK7/Exatecan Antibody-drug Conjugate LY4175408ruleEli Lillyphase 111 running–NCIt

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.